InvestorsHub Logo
icon url

rozzy

10/23/10 10:44 AM

#9852 RE: fxcm77 #9851

approved for what?? I am waiting
for FDA approval, nothing to do with nov 2nd..
icon url

newmedman

10/23/10 10:48 AM

#9854 RE: fxcm77 #9851

Where do you guys keep coming up with this stuff? This is right off of OTC

Profile Data
SIC - Industry Classification 1311 - Crude petroleum and natural gas
Business Status Development Stage Company
Incorporated In: NV, USA
Year of Inc. 1998
Employees 10 a/o Jun 17, 2010
Company Officers
Robert Jean Melamede CEO
Richard Cowan CFO
Mark Friedman IR

I see at least 10 employees as of June.....Probably more now with the JV,s of rockbrook and smokefree.

Rockbrook is paying an upfront licensing fee....REVENUE

not to mention the 50/50 split of profits. These guys have only just begun. I'm waiting for Q3 report, as this will be the first quarter that shows revenue. November 2 is only another stepping stone.
icon url

wecap

10/23/10 10:50 AM

#9856 RE: fxcm77 #9851

I went to the website

they have no products

no revenue

jut ride the wave

i think we go up from here

then i am getting out
icon url

platero

10/23/10 10:50 AM

#9857 RE: fxcm77 #9851

These are mostly red herrings and here's why...

I've had my questions too, but most have been answered satisfactorily with a little research.

1. Though their board of directors consists of 2 employees, CBIS consists of a team of many more. I have written a lot here about how what a great team of scientific and policy experts CBIS has (see here http://www.cannabisscience.com/corporate-info.html). We're talking about very experienced legal experts from the MMJ community, and doctors and PhD's with years of experience in the fields of disease treatment/prevention and natural medicines.

2. The success of CBIS does not depend on Nov 2. Sure passing Prop 19 will provide short-term confidence in a news media type of way. But CBIS long-term mission is not dependent upon the ending of prohibition in CA. CBIS' mission is a medical one with greater dependence on the medical marijuana community that has existed for over 10 years and is growing stronger across the country.

3. CBIS is currently awaiting FDA approval for development and clinical trials of a natural cannabis medicine. If it takes a year, or if it takes 3 years, its going to happen my friend. When it does, CBIS is positioned to be the leader in this unique, huge market. But meanwhile, there is much to be done without FDA approval like working with existing legal cannabis business in Colorado and working with SFIO to develop a product that could be launched sooner than we think outside the US.

In the end, each person must decide for him/herself what is the best play, what are you in this for, and do you really know enough about the company to be "holding large position" as you say. Take some time to read through their research and news release pages, and you'll get a better understanding for CBIS' long-term mission and diversity of options for leading the US canna-pharma market:

http://www.cannabisscience.com/research-a-development.html
http://www.cannabisscience.com/news-a-media/press-releases.html
icon url

Monksdream

10/23/10 5:35 PM

#9925 RE: fxcm77 #9851

Based on my limited experience, guys who aren't so good at the American English who buy shares of pink sheet and OTC:BB stocks also aren't so knowlegeable about the pink sheet and OTC:BB stock network.

As a rule, the percentage is so close to 100 percent, one might as well say that "all of them" currently produce and have never produced revenues of any significance.

That said, anyone who buys shares is buying shares on a purely speculative basis.

Historically speaking, what is now known as the "pink sheet quotation system" has its roots in America going back to 1904.

Since then, not a few thousand companies, not a few tens of thousands of companies, but in reality, one hundreds of thousands of companies have been quoted on the "pink sheets" since 1904.

That said, all I can is, "this time, it's different."

You've gotten in on the ground floor. You're going to be stinking rich.

In the next 2 to 3 years, Cannabis Science will become a component of the Standard & Poor's 500 Index, the most important and widely followed stock index on the planet.

Tout de Swing
Monksdream